Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
Total Valuation
Larimar Therapeutics has a market cap or net worth of $113.97M. The enterprise value is $68.61M.
Market Cap$113.97M
Enterprise Value$68.61M
Share Statistics
Larimar Therapeutics has 64.03M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64.03M
Owened by Insiders35.24%
Owened by Instutions0.34%
Financial Efficiency
Larimar Therapeutics’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -51.37%.
Return on Equity (ROE)-46.91%
Return on Assets (ROA)-40.26%
Return on Invested Capital (ROIC)-51.37%
Return on Capital Employed (ROCE)-51.68%
Revenue Per Employee$0
Profits Per Employee-$1,240,061.538
Employee Count65
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Larimar Therapeutics is -2.94. Larimar Therapeutics’s PEG ratio is -0.05.
PE Ratio-2.94
PS Ratio0.00
PB Ratio1.38
Price to Fair Value1.38
Price to FCF-3.33
Price to Operating Cash Flow-3.35
PEG Ratio-0.05
Income Statement
In the last 12 months, Larimar Therapeutics had revenue of $0.00 and earned -$80.60M in profits. Earnings per share was -$1.32.
Revenue$0.00
Gross Profit-$241.00K
Operating Income-$90.89M
Pretax Income-$80.60M
Net Income-$80.60M
EBITDA-90.65M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -$70.76M and capital expenditures -$515.00K, giving a free cash flow of -$71.28M billion.
Operating Cash Flow-$70.76M
Free Cash Flow-$71.28M
Free Cash Flow per Share-$1.11
Dividends & Yields
Larimar Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-30.07%
Earnings Yield-34.00%
Stock Price Statistics
Beta1.49
52-Week Price Change-75.21%
50-Day Moving Average2.76
200-Day Moving Average5.83
Relative Strength Index (RSI)29.97
Average Volume (3m)921.15K
Important Dates
Larimar Therapeutics upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 24, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Larimar Therapeutics as a current ratio of 8.02, with Debt / Equity ratio of 0.03
Current Ratio8.02
Quick Ratio8.02
Debt to Market Cap0.02
Net Debt to EBITDA0.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Larimar Therapeutics has paid $36.72K in taxes.
Income Tax$36.72K
Effective Tax Rate0.00%
Enterprise Valuation
Larimar Therapeutics EV to EBITDA ratio is -2.30, with an EV/FCF ratio of -2.93.
EV to Sales0.00
EV to EBITDA-2.30
EV to Free Cash Flow-2.93
EV to Operating Cash Flow-2.95
Balance Sheet
Larimar Therapeutics has $183.45M in cash and marketable securities with $5.12M in debt, giving a net cash position of -$178.34M billion.
Cash & Marketable Securities$183.45M
Total Debt$5.12M
Net Cash-$178.34M
Net Cash Per Share-$2.79
Tangible Book Value Per Share$2.80
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Larimar Therapeutics is $18.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$18.86
Price Target Upside941.99%
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast
EPS Growth Forecast-55.32%